Citation: Kc. Zachary et al., Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo, CLIN INF D, 33(12), 2001, pp. 2075-2077
Citation: Gj. Hanna et Rt. D'Aquila, Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy, CLIN INF D, 32(5), 2001, pp. 774-782
Authors:
Gilbert, PB
Hanna, GJ
De Gruttola, V
Martinez-Picado, J
Kuritzkes, DR
Johnson, VA
Richman, DD
D'Aquila, RT
Citation: Pb. Gilbert et al., Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens, AIDS RES H, 16(14), 2000, pp. 1325-1336
Authors:
Hanna, GJ
Johnson, VA
Kuritzkes, DR
Richman, DD
Martinez-Picado, J
Sutton, L
Hazelwood, JD
D'Aquila, RT
Citation: Gj. Hanna et al., Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase, J CLIN MICR, 38(7), 2000, pp. 2715-2721
Authors:
Martinez-Picado, J
DePasquale, MP
Kartsonis, N
Hanna, GJ
Wong, J
Finzi, D
Rosenberg, E
Gunthard, HF
Sutton, L
Savara, A
Petropoulos, CJ
Hellmann, N
Walker, BD
Richman, DD
Siliciano, R
D'Aquila, RT
Citation: J. Martinez-picado et al., Antiretroviral resistance during successful therapy of HIV type 1 infection, P NAS US, 97(20), 2000, pp. 10948-10953
Authors:
Hanna, GJ
Johnson, VA
Kuritzkes, DR
Richman, DD
Brown, AJL
Savara, AV
Hazelwood, JD
D'Aquila, RT
Citation: Gj. Hanna et al., Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine, J INFEC DIS, 181(3), 2000, pp. 904-911